Research by Li et al. [22] highlights the identification of wild-type isocitrate dehydrogenase 2 (IDH2) as a potential therapeutic target for a particularly aggressive subset of breast cancer known as triple-negative breast cancer (TNBC). The gene discussed is IDH2; the disease is breast carcinoma.